News | Implantable Cardioverter Defibrillators (ICD) | May 17, 2017

Subcutaneous ICD System Shows Positive Outcomes in Largest Real-world Study

Late-Breaker data on the Boston Scientific S-ICD presented at Heart Rhythm 2017

Boston Scientific S-ICD system with the subcutaneous lead

May 12, 2017 – Results from the U.S. post-market approval study evaluating “real-world” patients implanted with the Boston Scientific Subcutaneous Implantable Defibrillator (S-ICD) System is the largest S-ICD study to date. Data collected from the study were presented during a late-breaking clinical trial at Heart Rhythm 2017, the Heart Rhythm Society’s 38th Annual Scientific Sessions in Chicago, and demonstrated that physicians are implanting the S-ICD System largely for patients typically treated with transvenous implantable cardioverter defibrillators (TV-ICD) as well as for sicker patients while achieving a high success rate and low complication rate.

Acute results demonstrate the therapy effectively terminated life-threatening heart arrhythmias in 98.7 percent of evaluated patients. The S-ICD System analysis also validated low complication rates, with a complication-free rate of 96.2 percent at 30 days post-procedure.

“The ‘real-world’ population enrolled in the largest S-ICD study to date demonstrates that the device has low complication rates and very high success rates for terminating ventricular fibrillation,  thereby serving as an alternative treatment to transvenous ICDs,” said Michael R. Gold, M.D., Ph.D, U.S. principal investigator and Michael E. Assey professor of medicine at The Medical University of South Carolina, Charleston, S.C. “The population studied here is more similar to transvenous ICD populations compared to previous S-ICD studies, reinforcing this device can be used in a broad population of ICD-indicated patients.”

Watch a VIDEO showing how to implant the S-ICD system. 
 
The non-randomized registry, initiated in 2012 after the S-ICD System received U.S. Food and Drug Administration approval, included 1,637 patients implanted with the device at 86 U.S. medical centers. Nearly two-thirds of the patients evaluated in the study were primary prevention patients with a low ejection fraction, which represents the highest proportion of patients that are implanted with ICD devices. Additionally, more than half of the patients had comorbidities such as heart failure and hypertension, and more than 13 percent were on dialysis for end stage renal disease.
 
“Beyond the positive clinical outcomes, we are also seeing advancements in procedural techniques as physician experience and confidence continue to build,” said Kenneth Stein, M.D., senior vice president and chief medical officer, Global Health Policy and Rhythm Management, Boston Scientific. “Physicians are implanting over half of the devices with two surgical incisions rather than the standard three incisions and avoiding use of general anesthesia in more than one-third of patients.”
 
To further develop the clinical body of evidence in support of the S-ICD System, Boston Scientific initiated  a worldwide study called the Multicenter Automatic Defibrillator Implantation Trial with Subcutaneous Implantable Cardioverter Defibrillator (MADIT S-ICD) last month. The study will evaluate the survival benefit of  patients treated with the Emblem MRI S-ICD System – the latest generation S-ICD system – who are aged 65 and older with a history of prior heart attack, diabetes and moderately reduced left ventricular ejection fraction.
 

Related S-ICD Content:

Advances in Implantable Cardioverter Defibrillator (ICD) Technology

FDA Clears MRI-safe Subcutaneous Implantable Cardioverter Defibrillator (S-ICD) System

Positive Long-Term Outcomes For S-ICD System In the EFFORTLESS Study

 

For more information: www.sicdsystem.com

Related Content

New Multi-Center Research Effort to Focus on Early Life Origins of Heart Health
News | Congenital Heart| June 23, 2017
Heart health in children will be the focus of three closely synergistic research projects and an integrated...
Feature | EP Lab| June 22, 2017 | Dave Fornell
Electrophysiology (EP) technology has been advancing rapidly the past few years with new ablation tools to improve ar
Pacemakers and Other Cardiac Devices Can Help Solve Forensic Cases
News | Pacemakers| June 20, 2017
Pacemakers and other cardiac devices can help solve forensic cases, according to a study presented at the European...
BioTrace Medical's Tempo Lead Shows Stability and Safety in Real-World Performance
News | Leads Implantable Devices| June 20, 2017
BioTrace Medical Inc. announced that the company’s Tempo Temporary Pacing Lead was featured in an oral presentation and...
BioImage-2 Study to Investigate Atherosclerotic Disease Progression
News | Cardiovascular Ultrasound| June 20, 2017
Mount Sinai Heart and BioImage-2 LLC recently announced the start of the BioImage-2 study investigating the progression...
News | June 12, 2017
June 12, 2017 – Med Alliance announced completion on schedule of patient enrollment in the first-in-man (FIM) study o
Sponsored Content | Videos | Business| June 06, 2017
Andrea Natale, M.D., FACC, FHRS, FESC, executive medical director, Texas Cardiac Arryhthmia Institute at St.
Biosense Webster's multi-electrode RF ablation balloon

The most popular technology in May was the first data released on Biosense Webster's multi-electrode RF ablation balloon with irrigation. The system allows operators to change the energy levels of each electrode to avoid damaging sensitive underlying critical structures like the esophagus or phrenic nerve.

Feature | June 01, 2017 | Dave Fornell
June 1, 2017 — Here is the list of the most popular pieces of content on the Diagnostic and Interventional Cardiology
Infab Introduces Revolution Lead Aprons
Technology | Radiation Dose Management| June 01, 2017
June 1, 2017 — Infab Corp.
Sponsored Content | Videos | Implantable Cardioverter Defibrillators (ICD)| June 01, 2017
Lucas Boersma, M.D., Ph.D., FESC, St.
Overlay Init